Selection-based design of in silico dengue epitope ensemble vaccines


Dengue virus affects approximately 130 countries. 25% of infections result in febrile, self‐limiting illness; heterotypic infection results in potentially fatal Dengue Haemorrhagic Fever or Dengue Shock Syndrome. Only one vaccine is currently available. Its efficacy is very variable. Thus, to target Dengue, we used an innovative immunoinformatic protocol to design a putative epitope ensemble vaccine by selecting an optimal set of highly‐conserved epitopes with experimentally‐verified immunogenicity. From 1597 CD4+ and MHC II epitopes, 6 MHC Class I epitopes (RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, NMIIMDEAHF, KTWAYHGSY, WAYHGSYEV) and 9 MHC Class II epitopes (LAKAIFKLTYQNKVV, GKIVGLYGNGVVTTS, AAIFMTATPPGSVEA, AAIFMTATPPGTADA, GKTVWFVPSIKAGND, KFWNTTIAVSMANIF, RAIWYMWLGARYLEF, VGTYGLNTFTNMEVQ, WTLMYFHRRDLRLAA) were selected; this candidate vaccine achieved a world population coverage of 92.49%.

Publication DOI:
Divisions: College of Health & Life Sciences > Aston Pharmacy School
College of Health & Life Sciences
College of Health & Life Sciences > Chronic and Communicable Conditions
Additional Information: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.© 2018 The Authors.
Publication ISSN: 1747-0285
Last Modified: 08 Dec 2023 10:46
Date Deposited: 26 Jun 2018 13:05
Full Text Link:
Related URLs: https://onlinel ... 1111/cbdd.13357 (Publisher URL)
PURE Output Type: Article
Published Date: 2019-01
Published Online Date: 2018-11-25
Accepted Date: 2018-06-10
Authors: Murphy, David
Reche, Pedro
Flower, Darren R (ORCID Profile 0000-0002-8542-7067)



Version: Published Version

License: Creative Commons Attribution

| Preview


Version: Accepted Version

Access Restriction: Restricted to Repository staff only

Export / Share Citation


Additional statistics for this record